Pfizer Inc. $PFE Shares Sold by Lighthouse Financial LLC

Lighthouse Financial LLC reduced its holdings in shares of Pfizer Inc. (NYSE:PFE) by 22.0% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 8,863 shares of the biopharmaceutical company’s stock after selling 2,500 shares during the period. Lighthouse Financial LLC’s holdings in Pfizer were worth $215,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the business. GKV Capital Management Co. Inc. purchased a new stake in Pfizer during the 1st quarter worth $27,000. Curio Wealth LLC raised its position in Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 1,098 shares during the period. Bayforest Capital Ltd acquired a new position in shares of Pfizer during the first quarter worth about $28,000. Harbor Asset Planning Inc. purchased a new stake in shares of Pfizer in the second quarter worth about $29,000. Finally, WPG Advisers LLC purchased a new stake in shares of Pfizer in the first quarter worth about $35,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 0.0%

Shares of NYSE PFE opened at $25.06 on Tuesday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The stock’s 50 day moving average price is $24.81 and its two-hundred day moving average price is $24.45. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.69. The stock has a market capitalization of $142.47 billion, a P/E ratio of 13.33, a PEG ratio of 0.81 and a beta of 0.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. The business had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio is 100.00%.

Wall Street Analyst Weigh In

Several brokerages recently commented on PFE. The Goldman Sachs Group reiterated a “neutral” rating and set a $26.00 target price on shares of Pfizer in a report on Wednesday, November 5th. UBS Group reaffirmed a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research report on Wednesday, October 1st. Sanford C. Bernstein reissued a “market perform” rating and set a $30.00 target price on shares of Pfizer in a research report on Friday, October 31st. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Finally, Bank of America raised their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $28.28.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.